Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions

Management Board endorsement starts countdown for stakeholders to get ready for launch of improved system in November 2017

The European Medicines Agency (EMA) will launch a new and improved version of EudraVigilance, the European information system of suspected adverse reactions to medicines that are authorized or being studied in clinical trials in the European Economic Area (EEA). The new version of EudraVigilance will go live on 22 November 2017 with enhanced functionalities for reporting and analyzing suspected adverse reactions.